298 related articles for article (PubMed ID: 33456567)
21. Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.
Ma D; Fang Q; Wang P; Gao R; Wu W; Lu T; Cao L; Hu X; Wang J
J Biol Chem; 2015 May; 290(20):12558-71. PubMed ID: 25802333
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
[TBL] [Abstract][Full Text] [Related]
23. Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib.
Hrdinova T; Toman O; Dresler J; Klimentova J; Salovska B; Pajer P; Bartos O; Polivkova V; Linhartova J; Machova Polakova K; Kabickova H; Brodska B; Krijt M; Zivny J; Vyoral D; Petrak J
Int J Oncol; 2021 Feb; 58(2):238-250. PubMed ID: 33491750
[TBL] [Abstract][Full Text] [Related]
24. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
25. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
[TBL] [Abstract][Full Text] [Related]
26. Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
Li X; Pang J; Xue W; Wang Y; Tian T; Elgehama A; Wu X; Wu X; Sun Y; Qiu H; Shen Y; Xu Q
Toxicol Appl Pharmacol; 2018 Dec; 360():249-256. PubMed ID: 30290167
[TBL] [Abstract][Full Text] [Related]
27. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
Wang XY; Sun GB; Wang YJ; Yan F
Biol Pharm Bull; 2020; 43(10):1526-1533. PubMed ID: 32999163
[TBL] [Abstract][Full Text] [Related]
28. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
Farhadi E; Zaker F; Safa M; Rezvani MR
Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
[TBL] [Abstract][Full Text] [Related]
29. AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p.
Pan D; Yang W; Zeng Y; Li W; Wang K; Zhao L; Li J; Ye Y; Guo Q
Cell Signal; 2021 Aug; 84():110038. PubMed ID: 33984486
[TBL] [Abstract][Full Text] [Related]
30. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
31. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
32. SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia.
Sinnakannu JR; Lee KL; Cheng S; Li J; Yu M; Tan SP; Ong CCH; Li H; Than H; Anczuków-Camarda O; Krainer AR; Roca X; Rozen SG; Iqbal J; Yang H; Chuah C; Ong ST
Leukemia; 2020 Jul; 34(7):1787-1798. PubMed ID: 32051529
[TBL] [Abstract][Full Text] [Related]
33. LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis.
Han Y; Ma Z
Anticancer Drugs; 2021 Apr; 32(4):427-436. PubMed ID: 33587348
[TBL] [Abstract][Full Text] [Related]
34. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J
J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201
[TBL] [Abstract][Full Text] [Related]
35. CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
Huang SY; Liu YH; Chen YJ; Yeh YY; Huang HM
J Cell Physiol; 2018 Sep; 233(9):7467-7479. PubMed ID: 29663362
[TBL] [Abstract][Full Text] [Related]
36.
Kc R; Thapa B; Ubeda A; Jiang X; Uludağ H
Stem Cells Dev; 2019 Jun; 28(11):734-744. PubMed ID: 30585758
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
38. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
39. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
40. HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells.
Chen SH; Chow JM; Hsieh YY; Lin CY; Hsu KW; Hsieh WS; Chi WM; Shabangu BM; Lee CH
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31071955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
